& Events
& Events
News
& Events
Jan 17, 2022 Inversago Pharma Completes Phase 1 Clinical Trial on First-in-Class, Peripheral CB1 Blocker and Provides Strategy Update
Company has completed the Phase 1 Clinical Trial for its INV-202 molecule Encouraging Phase 1 results and supportive preclinical package assist in the launch of Phase 2 clinical development Metabolic disorders are a global epidemic 1 Montreal, Canada – 17 January 2022 – Inversago Pharma Inc. (“Inversago”), the peripheral CB1 blockade company, announced today the […]
Jan 10, 2022 Inversago Pharma Appoints Karine Lalonde, MSc to the position of Vice-President, Clinical Operations
MONTREAL (CANADA) – January 10, 2022 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Karine Lalonde, MSc as Vice-President, Clinical Operations, effective immediately. With 20 years of experience in clinical research operations, she brings to Inversago’s drug development program proven abilities in seamless clinical trial […]
Oct 25, 2021 Inversago Pharma Appoints Michael D. Harvey, PhD to the position of Chief Development Officer
MONTREAL (CANADA) – October 25, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Michael D. Harvey, PhD as Chief Development Officer (CDO), effective immediately. With over 20 years of experience and a proven track record in the pharmaceutical and biotechnology industry, Dr. Harvey will […]
Sep 7, 2021 Inversago Pharma Initiates a Phase 1 Clinical Trial on INV-202, a Next Generation Peripherally-acting CB1 Blocker
MONTREAL (CANADA) – September 7th, 2021 – Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced that following the receipt of a No Objection Letter (NOL) from Health Canada on July 29, 2021, it has dosed the first volunteers with INV-202 in its first-in-human phase 1 clinical trial, which will […]
